What is the total enterprise value and per-share price Merck KGaA has agreed to pay for Bio-Techne Corp.?

Merck KGaA has agreed to acquire Bio-Techne Corp. for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion.

What premium does Merck's offer represent relative to Bio-Techne's recent trading price?

The $73-per-share offer represents a 36% premium to Bio-Techne’s one-month volume weighted average trading price.

Merck to Acquire US-Based Life Sciences Firm Bio-Techne for $11.3 Billion

Jun 26, 2026

Merck KGaA has entered a definitive agreement to acquire Bio-Techne Corp for $73 per share in cash, totaling approximately $11.3 billion. The transaction offers a 36% premium over Bio-Techne's recent trading price.

chemweek

2026-06-25

Merck KGaA to Acquire Bio-Techne for $11.3 Billion

2026-06-26

Merck to Acquire US-Based Life Sciences Firm Bio-Techne for $11.3 Billion

2026-09-09

Merck KGaA Buys PostEra’s Oral Fertility Molecules

2026-10-19

Merck KGaA Acquires Silence Therapeutics for $1.3 Billion

Merck to Acquire US-Based Life Sciences Firm Bio-Techne for $11.3 Billion

FAQ